Investor Presentation - FDA Submission for CTVQ
Filed with ASX · · 34 pages · English
Summary by 6ix AI
It highlights the completion of clinical evaluations and the strong correlation of CT:VQ results with traditional imaging techniques. The document emphasizes the importance of regulatory clearance for commercial use and the expected impact on lung health diagnostics.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from 4DMedical
- 4DMedical files FDA submission for CTVQ
- 4DMedical wins commercial contract with Intermountain Health
- Quarterly Activity Report and Appendix 4C for Q3 FY2025
- Supplementary Prospectus
- 4DMedical converts Integral Diagnostics pilot into contract
Later from 4DMedical
- Olympus launches new SeleCT Screening campaign
- 4DMedical contract with Stanford, includes CTVQ
- Lung Scan Technology Reveals Hidden Secrets of Airway Disease
- 4DMedical renews 3 year contract with University of Michigan
- 4DMedical secures $10mstrategic invest' from Pro Medicus
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical